Top View
- Computational Study of Drugs Targeting Nuclear Receptors Deleted: Endocrine-Disrupting Potential of Medicines
- For the Treatment of Patients with Relapsed Or Refractory Chronic
- Chronic Lymphocytic Leukemia (CLL) Natural History
- July 2016 Welcome to the Latest Issue of Evaluate’S Calendar of Events Newsletter, Your Monthly Digest of Upcoming Events in the Industry
- NH Healthy Families Pharmacy & Therapeutics Committee Q2 2020 Guideline Summary
- Download Supplementary
- Therapeutic Advances in Oncology
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- State and Specialty Pharmacy Drug Reimbursement Rates
- Supplementary Table 1. Summary of FDA-Approved Anticancer Cytotoxic Drugs at May 2019
- Oncology Medications Policy (1403)
- Review of Venetoclax in CLL, AML and Multiple Myeloma
- Appendix a - Product Name Index
- PI3K) Inhibitors
- Emetogenic Potential of Antineoplastic Agents
- Phase I Study of BGT226, a Pan-PI3K and Mtor Inhibitor, in Japanese
- Withdrawal Assessment Report
- Oncology Proposal
- Multi-Discipline Review/Summary, Clinical, Non
- State and Specialty Pharmacy Drug Reimbursement Rates
- Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients With
- New Century Health Policy Changes May 2021
- Study Protocol Ipi-145-07
- Duvelisib in Inflammation Asthma ASPIRA (RA)
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/Mtor, Aurora Kinase and EZH2 Inhibitors
- Standard Oncology Criteria Policy Number: Pending
- Pathways Inhibitors for CLL Therapy
- Actions of Pi3k-Delta Inhibitor, Idelalisib, and Its Combination with Bendamustine in Chronic Lymphocytic Leukemia
- Duvelisib), Overcomes Signals from the PI3K/AKT/S6 Pathway and Promotes Apoptosis in CLL
- Oncology Agents
- Duvelisib (Copiktra®) EOCCO POLICY
- November 2020
- Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL